Scarica Oncology Nursing Drug Handbook - v3.5.13

Hai sentito parlare di Oncology Nursing Drug Handbook - v3.5.13, o MCQ Abubakr (ASU), iDentist Dental practice management, Inject App, Medical PG, FMGE Preparation - PrepLadder, X-RAY WOW, Medical Dictionary Free & Offline - Diseases, uno dei più interessanti App della categoria Medicina.

E ovviamente lo sai, non tutti i giochi o le applicazioni sono compatibili con tutti i telefoni. Il gioco o l'applicazione a volte non è disponibile sul tuo dispositivo, dipende dalla versione del sistema. Sistema operativo Android, risoluzione dello schermo o paesi a cui Google Play consente l'accesso. Ecco perché APKPanda fornisce file APK Android da scaricare e non si attiene a queste restrizioni.>
Oncology Nursing Drug Handbook - v3.5.13 l'ultima versione è 3.5.13, data di rilascio 2020-06-25 e dimensione 8.4 MB.Sviluppato da Skyscape Medpresso Inc, Oncology Nursing Drug Handbook - v3.5.13 richiede almeno la versione Android Android 5.0+. Pertanto è necessario aggiornare il telefono se necessario.

Piuttosto caricato, circa 1000 download. Puoi aggiornare le app che sono state scaricate o installate singolarmente sul tuo dispositivo Android, se lo desideri. L'aggiornamento delle tue app ti dà il permesso di accedere alle funzioni più recenti e migliora la sicurezza e la stabilità delle applicazioni.

Written especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.

DESCRIPTION
Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA.

Key Features

- Provides valuable information on effective symptom management, patient education, and chemotherapy administration.
- Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies
- Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer
- Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs
- New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™)

Faster download with slow internet connectivity